Association of serum interleukin‐17 and interleukin‐23 levels with disease activity in Chinese patients with ankylosing spondylitis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of the Chinese Medical Association

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jcma.2012.05.006PMID 22824043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the T helper 17 axis in ankylosing spondylitis

  2012cited by this paper
• Mast cells express IL-17A in rheumatoid arthritis synovium.

  2010cited by this paper
• Pathogenesis of ankylosing spondylitis

  2010cited by this paper
• Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis

  2009cited by this paper
• Interleukin-17 and type 17 helper T cells.

  2009cited by this paper
• Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis.

  2009cited by this paper
• Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients

  2009cited by this paper
• Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply

  2008cited by this paper
• gammadelta T cells: an important source of IL-17.

  2008cited by this paper
• The interleukin-23/interleukin-17 axis in spondyloarthritis

  2008cited by this paper
• Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

  2008cited by this paper
• Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.

  2008cited by this paper
• Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis.

  2007cited by this paper
• Th17 cells: effector T cells with inflammatory properties.

  2007cited by this paper
• Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.

  2007cited by this paper
• Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.

  2007cited by this paper
• Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis.

  2007cited by this paper
• Comparison of serum IL-1β, sIL-2R, IL-6, and TNF-α levels with disease activity parameters in ankylosing spondylitis

  2006cited by this paper
• Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.

  2006cited by this paper
• The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis.

  2005cited by this paper
• Increased expression of interleukin 17 in inflammatory bowel disease

  2003cited by this paper
• Increased interleukin-17 production in patients with systemic sclerosis.

  2000cited by this paper
• Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus

  2000cited by this paper
• Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.

  1999cited by this paper
• Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review.

  1999cited by this paper
• Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium.

  1999cited by this paper
• Cytokines and the hepatic acute phase response

  1997cited by this paper
• The Bath Ankylosing Spondylitis Patient Global Score (BAS-G).

  1996cited by this paper
• A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

  1994cited by this paper
• A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

  1994cited by this paper
• Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis.

  1986cited by this paper
• Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

  1984cited by this paper
• The pathogenesis of ankylosing spondylitis.

  1975cited by this paper
• [Erythematosus].

  1971cited by this paper

• Is there an anti-inflammatory effect of aerobic exercises on axial spondyloarthropathy patients? A prospective, randomized-controlled trial

  2025cites this paper
• Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block

  2025cites this paper
• IL-23/IL-17 axis in the pathogenesis and therapy of axial spondyloarthritis associated with inflammatory

  2025cites this paper
• Elevated serum interleukin-41 levels as a potential biomarker in ankylosing spondylitis

  2025cites this paper
• Ankilozan Spondilit Hastalarında Serum IL-17 ve TNF-Alfa Düzeyi ile Hastalık Aktivitesi Arasındaki İlişki

  2025cites this paper
• Novel therapies for axial spondyloarthritis and future directions.

  2025cites this paper
• The association between ankylosing spondylitis and the risk of venous thromboembolism: a meta-analysis

  2025cites this paper
• Inflammatory bowel disease activity threatens ankylosing spondylitis: implications from Mendelian randomization combined with transcriptome analysis

  2024cites this paper
• Regnase-1 regulates inflammation in T cells of ankylosing spondylitis through the TRAF6

  2024cites this paper
• Dysregulated Non-Coding RNA Expression in T Cells from Patients with Ankylosing Spondylitis Contributes to Its Immunopathogenesis

  2024cites this paper
• Determination of IL-23 receptor expression and gene polymorphism (rs1884444) in Iranian patients with ankylosing spondylitis

  2024cites this paper
• The role of ixekizumab in the treatment of nonradiographic axial spondyloarthritis.

  2024cites this paper
• Pro-inflammatory cytokines in spondyloarthritis: a case-control study

  2024influential citation
• Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials

  2023cites this paper
• Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases.

  2023cites this paper
• Value of ischemia-modified albumin in ankylosing spondylitis

  2023cites this paper
• Correlation of serum subfatin, cthrc1, ctrp3, ctrp6 levels with disease indices in patients with axial spondyloarthritis

  2023cites this paper
• Retrospective Comparison of the Effect of IL-17 Blocker Therapy and Anti-TNF Agent Therapy on Bone Mineral Density in Axial Spondyloartropathy Patients

  2023cites this paper
• Have Therapeutics Enhanced Our Knowledge of Axial Spondyloarthritis?

  2023cites this paper
• Association of Serum Interleukin-17 and Interleukin-23 Levels with Disease Activity, Function, Mobility, Enthesitis Index in Patients with Ankylosing Spondylitis

  2022cites this paper
• Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium”

  2022cites this paper
• Joint together: The etiology and pathogenesis of ankylosing spondylitis

  2022cites this paper
• Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis

  2022cites this paper
• The role of ixekizumab in non-radiographic axial spondyloarthritis

  2021cites this paper
• Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis

  2021cites this paper
• The Relationship between Disease Activity, Quality of Life, Functional Status, Spinal Mobility, Heel Enthesitis, and Cartilage Thickness in Patients with Axial Spondyloarthritis: A Cross-Sectional Study

  2021cites this paper
• B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis

  2021cites this paper
• Rodent Models of Spondyloarthritis Have Decreased White and Bone Marrow Adipose Tissue Depots

  2021cites this paper
• Similarities and Differences Between Juvenile and Adult Spondyloarthropathies

  2021cites this paper
• Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis

  2021cites this paper
• Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers.

  2021cites this paper
• IL-17 AND DISEASE ACTIVITY IN SPONDYLOARTHRITIS

  2021cites this paper
• Biological and genetic evaluation of IL-23/IL-17 pathway in ankylosing spondylitis patients

  2020cites this paper
• Risk of ankylosing spondylitis following human papillomavirus infection: A nationwide, population-based, cohort study.

  2020cites this paper
• Biomarker development for axial spondyloarthritis

  2020cites this paper
• Exames complementares das entesopatias. Parte 1 – Biomarcadores

  2020cites this paper
• Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis

  2020cites this paper
• Spondyloarthritis patients with and without intestinal symptoms – searching for discriminating biomarkers

  2020cites this paper
• Evaluation of Interleukin-23 and JAKs/STATs/SOCSs/ROR-γt Expression in Type 2 Diabetes Mellitus Patients Treated With or Without Sitagliptin

  2020cites this paper
• The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis

  2020influential citation
• Circulating interleukin-23 levels in ankylosing spondylitis and their correlation with disease activity

  2020influential citation
• Copy number variation of IL17RA gene and its association with the ankylosing spondylitis risk in Iranian patients: a case-control study

  2020cites this paper
• An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision

  2020cites this paper
• Serological Biomarkers in Early Axial Spondyloarthritis During 24-Months Follow Up (Italian Arm of Space Study)

  2019cites this paper
• Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function

  2019cites this paper
• Association between interleukin-17A/F single nucleotide polymorphisms and susceptibility to osteoarthritis in a Chinese population

  2019cites this paper
• IL-17 inhibition in axial spondyloarthritis: current and future perspectives

  2019cites this paper
• Disease Activity and Patient-Reported Health Measures in Relation to Cytokine Levels in Ankylosing Spondylitis

  2019cites this paper
• Systemic effects of IL-17 in inflammatory arthritis

  2019cites this paper
• Elevated circulating IL-17 level is associated with inflammatory arthritis and disease activity: A meta-analysis.

  2019cites this paper
• Serum Interleukin-23/17 Levels in Ankylosing Spondylitis Patients Treated with Nonsteroidal Anti-Inflammatory Drugs: A Prospective Cohort Study

  2019cites this paper
• Serum Interleukin 23 in Psoriatic Arthritis Patients: Relation to disease activity, physical function and health related quality of life

  2019cites this paper
• The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systemic Review and Meta-Analysis

  2018cites this paper
• IL-17 in the immunopathogenesis of spondyloarthritis

  2018cites this paper
• Novel Insights in Ankylosing Spondylitis Biology: Mouse and Human Studies

  2018cites this paper
• Association of IL-23R gene single nucleotide polymorphism; rs 11209026 with incidence and severity of ankylosing spondylitis in a cohort of Egyptian patients

  2018cites this paper
• Role of Interleukin- (IL-) 17 in the Pathogenesis and Targeted Therapies in Spondyloarthropathies

  2018cites this paper
• High-Fat Meal–Induced Changes in Markers of Inflammation and Angiogenesis in Healthy Adults Who Differ by Age and Physical Activity Level

  2018cites this paper
• Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis

  2018influential citation
• NLRP3 inflammasomes and NLRP3 inflammasome-derived proinflammatory cytokines in peripheral blood mononuclear cells of patients with ankylosing spondylitis.

  2018cites this paper
• The effect of single nucleotide polymorphism on susceptibility of osteoarthritis: recent progression and implications

  2017cites this paper
• Chapter 74 – Etiology and Pathogenesis of Spondyloarthritis

  2017cites this paper
• Associations between serum levels of interleukin-23 and the susceptibility and development of ankylosing spondylitis : a meta-analysis

  2017cites this paper
• An update on biomarker discovery and use in axial spondyloarthritis

  2017cites this paper
• Increased interleukin (IL)‐17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti‐IL‐17 agents

  2017cites this paper
• The Diagnostic and Prognostic Role of Interleukin 12B and Interleukin 6R Gene Polymorphism in Patients With Ankylosing Spondylitis

  2017cites this paper
• The role of innate immune cells in tissue inflammation in spondyloarthritis

  2017cites this paper
• An update on biomarkers in axial spondyloarthritis.

  2016cites this paper
• Associations between polymorphisms of IL-17F and IL-17A genes with disease activity and clinical outcome of Ankylosing Spondylitis.

  2016cites this paper
• IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients

  2016cites this paper
• Mediators of inflammation and bone remodeling in rheumatic disease.

  2016cites this paper
• Elevated Serum Levels of Sclerostin are Associated with High Disease Activity and Functional Impairment in Patients with Axial Spondyloarthritis.

  2016cites this paper
• Circulating levels of Th1 and Th2 chemokines in patients with ankylosing spondylitis.

  2016cites this paper
• INTERLEUKIN (IL) 12, IL-23 AND IL-23 RECEPTOR IN ANKYLOSING SPONDYLITIS PATHOPHYSIOLOGY

  2015cites this paper
• The Effect of Il-23 Levels on Clinical and Laboratory Parameters of Patients with Ankylosing Spondylitis

  2015cites this paper
• IL-17 Inhibition in Axial Spondyloarthritis

  2015cites this paper
• Involvement of Th 17 pathway in spondyloarthritis.

  2015cites this paper
• The ongoing quest for biomarkers in Ankylosing Spondylitis

  2015cites this paper
• The IL-23/Th 17 pathway in spondyloarthritis: the royal road?

  2015cites this paper
• Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis

  2015cites this paper
• Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis.

  2015influential citation
• Elevated serum interleukin-23 levels in ankylosing spondylitis patients and the relationship with disease activity

  2015cites this paper
• Inflammatory bowel disease-related arthritis – clinical evaluation and possible role of cytokines

  2015cites this paper
• Study of the relationships between IL-23R, IL-17, IL-21 polymorphisms and serum level of IL-17, IL-21 with acute graft rejection in iranian liver transplant recipients

  2014cites this paper
• Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases

  2014cites this paper
• Th17 Cells in Autoimmune and Infectious Diseases

  2014cites this paper
• L’axe IL-23/Th17 dans la spondyloarthrite : la voie royale ?☆

  2014cites this paper
• Review: The Interleukin‐23/Interleukin‐17 Axis in Spondyloarthritis Pathogenesis: Th17 and Beyond

  2014cites this paper
• Association of IL-17A and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a Korean population.

  2014cites this paper
• Elevated Serum Levels of Calprotectin (Myeloid-Related Protein 8/14) in Patients With Ankylosing Spondylitis and Its Association With Disease Activity and Quality of Life

  2014cites this paper
• Osteoclast activity in ankylosing spondylitis patients before and after TNF-blocking therapy

  2014cites this paper
• Artritis psoriásica: Contribuciones al conocimiento de su patogenia, de sus comorbilidades y al perfil de seguridad de su tratamiento

  2014cites this paper
• How to Translate Basic Knowledge into Clinical Application of Biologic Therapy in Spondyloarthritis

  2013cites this paper
• Elevated Serum Levels of Interleukin-17A in Uveitis Patients

  2013cites this paper
• Emerging drugs for axial spondyloarthritis including ankylosing spondylitis

  2013cites this paper